Anubhav Kaviratna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anubhav Kaviratna has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Abhinav Ram Mohan
Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA
1 shared publication - Bryan Newman
Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland
1 shared publication - Elizabeth Bielski
Office of Generic Drugs, Office of Research and Standards, Division of Therapeutic Performance-I, Food and Drug Administration, Silver Spring, USA
1 shared publication - Liangfeng Han
Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA
1 shared publication - Qiang Wang
Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA
1 shared publication - Sneha Dhapare
Division of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA
1 shared publication
Latest Publications
- Open Access
- 17 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2495
Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development
Dry powder inhalers (DPIs) are drug–device combination products where the complexity of the formulation, its interaction with the device, and input from users play important roles in the drug delivery. As the landscape of DPI products advances with new powder formulations and novel device designs, understanding how these advancements impact performance can aid in developing generics that are therapeutically equivalent to the reference listed drug (RLD) products. This review details the current understanding of the formulation and device related principles driving DPI performance, past and present research efforts to characterize these performance factors, and the implications that advances in formulation and device design may present for evaluating bioequivalence (BE) for generic development.
- 17 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2495
Open AccessAdvancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development
Dry powder inhalers (DPIs) are drug–device combination products where the complexity of the formulation, its interaction with the device, and input from users play important roles in the drug delivery. As the landscape of DPI products advances with new powder formulations and novel device designs, understanding how these advancements impact performance can aid in developing generics that are therapeutically equivalent to the reference listed drug (RLD) products. This review details the current understanding of the formulation and device related principles driving DPI performance, past and present research efforts to characterize these performance factors, and the implications that advances in formulation and device design may present for evaluating bioequivalence (BE) for generic development.